Cohance Lifesciences · NSE: COHANCE · BSE: 543064
Q1 FY21 results · Apr–Jun 2020
Cohance Lifesciences reported revenue from operations of ₹238.23 crore and net profit of ₹91.52 crore for Q1 FY21 (Apr–Jun 2020), on a consolidated basis.
| Item | Q1 FY21 | Q1 FY20 | YoY | Q4 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 238.23 | — | — | 184.76 | +28.9% |
| Other income | 5.74 | — | — | 5.34 | +7.5% |
| Total income | 243.97 | — | — | 190.10 | +28.3% |
| Profit before share of associates & JVs and tax | 107.55 | — | — | 68.41 | +57.2% |
| Share of profit/(loss) of associates & JVs | 10.32 | — | 20.97 | ||
| Net profit for the period | 91.52 | — | — | 74.18 | +23.4% |
| EPS, basic (₹) | 7.19 | — | — | 5.83 | +23.3% |
| Net margin (%) | 38.4 | — | 40.1 |
This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.
| Item | Q1 FY21 | Q1 FY20 | YoY | Q4 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 238.23 | — | — | 184.76 | +28.9% |
| Other income | 5.74 | — | — | 5.34 | +7.5% |
| Total income | 243.97 | — | — | 190.10 | +28.3% |
| Profit before tax | 107.58 | — | — | 68.44 | +57.2% |
| Net profit for the period | 81.23 | — | — | 53.24 | +52.6% |
| EPS, basic (₹) | 6.38 | — | — | 4.18 | +52.6% |
| Net margin (%) | 34.1 | — | 28.8 |
Consolidated
- Filed with BSE
- 18 Aug 2020, 12:27 IST
- Board meeting
- 17 Aug 2020
- Period
- 01 Apr 2020 to 30 Jun 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 18 Aug 2020, 12:27 IST
- Board meeting
- 17 Aug 2020
- Period
- 01 Apr 2020 to 30 Jun 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE